March 19, 2020
Firstly, please accept my best wishes for you, your family, friends and patients in these trying times. As the SARS-CoV-2 (COVID-19) virus pandemic continues to evolve at a rapid rate, we understand that this is a difficult and unsettling time for everyone.
As we move into uncharted territory, I would like to update you on Endologix’s plans for the next few weeks.
We at Endologix would like to convey our unremitting commitment to our physician partners and patients. We remain open for business and have organized our operational framework to prioritize physician support and patient care above all other ancillary activities. We intend to continue to manufacture and ship our AFX2, Ovation iX and Alto* products. We are continuing to transport our finished devices to forward stocking locations and to our field-based representatives to ensure continuity of supply and we will do our very best to meet emergent and urgent clinical needs.
It is obviously difficult to predict the effect that the pandemic will have on the healthcare systems around the world. We anticipate that the utilization of hospital facilities may be subject to changing priorities but given the nature of the disease we treat; we want to ensure that we are focused on providing you with the products you need to treat patients with AAA.
We remain ready to assist in clinical treatment of your patients through discussion, case planning, device provision and clinical support, if requested. Clearly we need to respect the changing healthcare environment, so we have asked our sales team to: minimize face-to-face interactions outside of clinical case support, abide by local hospital restrictions and applicable local and state ordinances, be available to you by phone and offer support through a compliant electronic upload facility for CT scans.
While situational factors surrounding the pandemic continue to evolve and circumstances can change, we want to keep you informed of our approach to these challenging times and reassure you that we are dedicated to providing the level of service to which you have become accustomed. We will continue to reach out to provide periodic updates as the pandemic evolves. In the meantime, if you have any questions or concerns please reach out to your local representative.
Matt Thompson, MD
Chief Medical Officer
* The Alto™ Abdominal Stent Graft System is not approved outside of the United States. CE Mark Pending.